Harte Hanks (HHS) Corporate Presentation from NobleCon18Research, News and Market Data on Harte HanksNobleCon 18 Complete Rebroadcast
|
Access to Exclusive Content. FREE for Registered Users Only.
Join the Channelchek Investor Community to access equity research, video content, events, and much more. All at no cost.
‌


Welcome to the Channelchek Investor Community
We’ve updated the entire site to bring you faster navigation and increased content at every level. Channelchek is now North America’s leading platform for access to regulated and independent company sponsored equity research.
Don't have an account? Join
Forgot passwordBy clicking “Log In” you agree to Channelchek.com Terms of Use and acknowledge that Channelchek.com Privacy Policy applies to you.
Related News
‌


2/25/2026
Health
Cadrenal Therapeutics (CVKD) – CAD-1005 Phase 2 Results Announced, With FDA Guidance Meeting Scheduled
Cadrenal Announced Phase 2 Data With End-of-Phase-2 Meeting Scheduled. Cadrenal announced data from the Phase 2 trial of its anti-thrombotic CAD-1005 (formerly known as VLX-1005) for HIT, or heparin-induced thrombocytopenia. Cadrenal...
2 min read
‌


2/25/2026
Aerospace and Defense
V2X (VVX) – A Strong End to the Year
Overview. In the fourth quarter, V2X drove record quarterly revenue, adjusted EBITDA, and adjusted cash flow. These results reflect the strength of the Company’s strategy and alignment with national security priorities...
2 min read
‌


2/25/2026
Basic Materials
InPlay Oil (IPOOF) – 2026 Guidance Points to Disciplined Growth and Continued Deleveraging
2026 guidance. InPlay approved a C$66 to C$74 million capital program targeting average production of 18,600 to 19,200 boe/d (~61% light oil and NGLs), representing approximately 11% growth over the estimated...
2 min read
Inbox Intel from Channelchek.
Informed investors make more money. And it’s all about timing. Get it when it happens.